Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Daniel Addison"'
Autor:
Nihar R. Desai, Amit K. Dey, Daniel Addison, Brijesh Patel, Michael G. Fradley, Arjun K. Ghosh, Juan Lopez-Mattei, Amitava Banerjee, Sadeer G. Al-Kindi, Avirup Guha, Guilherme H. Oliveira, Marcos de Lima, P. Elliott Miller
Publikováno v:
Am J Cardiol
Cancer patients face a higher risk of future myocardial infarction (MI), even after completion of anticancer therapies. MI is a critical source of physical and financial stress in non-cancer patients, but its impacts associated with cancer patients a
Autor:
Kyle Porter, Tyler Dickerson, Jennifer Philippon, Kerry A. Rogers, Jennifer A. Woyach, Seema A. Bhat, Daniel Addison, Tracy Wiczer, Avirup Guha, Allyson Waller, Devin Haddad, John C. Byrd, Farrukh T. Awan
Publikováno v:
Blood. 134:1919-1928
Ibrutinib is associated with dramatic efficacy against B-cell malignancies. Yet, ibrutinib is linked with potentially-limiting cardiotoxicity, including emerging reports of profound hypertension. However, the long-term incidence, severity, and impact
Autor:
Ajay Vallakati, Daniel Addison, Adam C. Calaway, Shelby Kutty, Anita Deswal, Nihar R. Desai, Azariyas A. Challa, Ragavendra R. Baliga, Jennifer Cullen, Neal L. Weintraub, Jorge A. Garcia, Avirup Guha, Courtney M. Campbell
Publikováno v:
Current Treatment Options in Oncology
Opinion statement Prostate cancer is the second leading cause of cancer death in men, and cardiovascular disease is the number one cause of death in patients with prostate cancer. Androgen deprivation therapy, the cornerstone of prostate cancer treat
Autor:
Daniel Addison, Robert Wesolowski, Bhuvaneswari Ramaswamy, Julie A. Stephens, Evan Morgan, Sagar Sardesai, Marilly Palettas, Jasmine Singh Sukumar, Daniel G. Stover, Jeffrey VanDeusen, Maryam B. Lustberg, Mathew Cherian, Nicole Williams, Mahmoud Kassem, Ragavendra R. Baliga
Publikováno v:
Cardio-oncology
Cardio-Oncology, Vol 6, Iss 1, Pp 1-9 (2020)
Cardio-Oncology, Vol 6, Iss 1, Pp 1-9 (2020)
Background Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth factor receptor 2 (HER2)-posi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cadb98c5b3243c8c2d2cbdd313702820
https://doi.org/10.21203/rs.3.rs-60091/v1
https://doi.org/10.21203/rs.3.rs-60091/v1
Autor:
Arjun K. Ghosh, Daniel Addison, Prantesh Jain, Sadeer G. Al-Kindi, Guilherme H. Oliveira, Marcos de Lima, Jahir M. Gutierrez, Claire Roddie, Avirup Guha
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 26(12)
Chimeric antigen receptor (CAR) T cell therapy is approved in the United States for the treatment of acute lymphocytic leukemia and aggressive B cell lymphomas. Multiple cardiovascular adverse events (CVEs) associated with CAR-Ts have been observed i
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Autor:
Arjun K. Ghosh, Sara Tyebally, Roohi Ismail-Khan, J Malcolm Walker, Vikas Kapil, Avirup Guha, Daniel H Chen, Daniel Addison, Robin Chung
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 9, Iss 3346, p 3346 (2020)
Journal of Clinical Medicine, Vol 9, Iss 3346, p 3346 (2020)
Cardiotoxicity is the umbrella term for cardiovascular side effects of cancer therapies. The most widely recognized phenotype is left ventricular dysfunction, but cardiotoxicity can manifest as arrhythmogenic, vascular, myocarditic and hypertensive t
Autor:
Michael T. Lu, Daniel Addison, Sumbal Janjua, Hamed Emami, Richard P. Cambria, Travis R. Hallett, Lori J. Wirth, Udo Hoffmann, Pedro V. Staziaki, Annie W. Chan, Sara B. Seidelmann, Bálint Szilveszter, Tomas G. Neilan
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Radiation therapy ( RT ) is a standard treatment for head and neck cancer; however, it is associated with inflammation, accelerated atherosclerosis, and cerebrovascular events ( CVEs ; stroke or transient ischemic attack). Human papillomav
Autor:
Jennifer A. Woyach, Mohamed H. Derbala, John C. Byrd, Farrukh T. Awan, Avirup Guha, Daniel Addison, Tracy Wiczer, Qiuhong Zhao
Publikováno v:
Journal of the American College of Cardiology. 72:697-698
Ibrutinib is a new Bruton’s tyrosine kinase inhibitor associated with improvements in the outcomes of various B-cell hematologic malignancies and is now standard lifelong therapy in those without intolerance or disease progression [(1)][1]. However
Autor:
Daniel Addison, Tracy Wiczer, Jennifer Philippon, Allyson Waller, Avirup Guha, Devin Haddad, Tyler Dickerson, Kyle Porter, Kerry A. Rogers, Jennifer A. Woyach, Farrukh T. Awan, John C. Byrd
Publikováno v:
Blood. 132:4423-4423
Background Ibrutinib (IB), a nonselective Bruton's tyrosine kinase inhibitor, is associated with significantly improved disease control rates, progression free, and overall survival in several B-cell malignancies. Yet, IB's nonselective actions may r